A prospective randomized phase II study evaluating the optimization of the residual plasmatic level of dasatinib (Sprycel®) in patients newly diagnosed with chronic phase chronic myelogenous leukaemia (CP-CML).
See Trial Description.
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society